NCT04991480 2026-01-27
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
Phase 1 Completed
Clinical Trials
16 trialsNCT04497116 2025-10-21
TRESR
Repare Therapeutics
Phase 1/2 Completed
NCT04672460 2024-09-25
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03343054 2024-08-22
A Phase 1 Study Of Talazoparib, PARP Inhibitor, In Japanese Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT03148795 2024-04-05
A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer
Pfizer
Phase 2 Completed
NCT05141708 2024-02-16
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
Pfizer
Completed
NCT04987931 2024-01-22
Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer
Pfizer
Completed
NCT02921919 2022-08-24
Open-Label Extension and Safety Study of Talazoparib
Pfizer
Phase 2 Completed
NCT01945775 2022-01-20
EMBRACA
Pfizer
Phase 3 Completed
NCT03077607 2021-06-30
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Pharmacokinetics of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT02997176 2021-02-25
An Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800)
Pfizer
Phase 1 Completed
NCT02997163 2021-01-05
An Open-Label Pharmacokinetics and Safety Study of Talazoparib
Pfizer
Phase 1 Completed
NCT03042910 2019-12-17
A Study to Assess the Effects of Talazoparib on Cardiac Repolarization in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01286987 2019-01-10
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
Pfizer
Phase 1 Completed
NCT03070548 2018-12-17
A Study of Talazoparib in Patients With Advanced Solid Tumors
Pfizer
Phase 1 Completed
NCT01399840 2017-09-15
Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies
Pfizer
Phase 1 Completed